PMC:7283670 / 88400-90346 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T295","span":{"begin":1681,"end":1685},"obj":"Body_part"}],"attributes":[{"id":"A295","pred":"fma_id","subj":"T295","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T186","span":{"begin":1681,"end":1685},"obj":"Body_part"}],"attributes":[{"id":"A186","pred":"uberon_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T478","span":{"begin":58,"end":83},"obj":"Disease"},{"id":"T479","span":{"begin":175,"end":183},"obj":"Disease"},{"id":"T480","span":{"begin":1738,"end":1763},"obj":"Disease"},{"id":"T481","span":{"begin":1836,"end":1855},"obj":"Disease"}],"attributes":[{"id":"A478","pred":"mondo_id","subj":"T478","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A479","pred":"mondo_id","subj":"T479","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A480","pred":"mondo_id","subj":"T480","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A481","pred":"mondo_id","subj":"T481","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T746","span":{"begin":65,"end":70},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T747","span":{"begin":195,"end":197},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T748","span":{"begin":326,"end":327},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T749","span":{"begin":386,"end":387},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T750","span":{"begin":503,"end":506},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T751","span":{"begin":851,"end":857},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T752","span":{"begin":930,"end":931},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T753","span":{"begin":990,"end":991},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T754","span":{"begin":1075,"end":1081},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T755","span":{"begin":1130,"end":1133},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T756","span":{"begin":1596,"end":1600},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T757","span":{"begin":1681,"end":1685},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T758","span":{"begin":1681,"end":1685},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T759","span":{"begin":1745,"end":1750},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

LitCovid-PD-CHEBI

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T760","span":{"begin":0,"end":270},"obj":"Sentence"},{"id":"T761","span":{"begin":271,"end":283},"obj":"Sentence"},{"id":"T762","span":{"begin":284,"end":392},"obj":"Sentence"},{"id":"T763","span":{"begin":393,"end":471},"obj":"Sentence"},{"id":"T764","span":{"begin":472,"end":548},"obj":"Sentence"},{"id":"T765","span":{"begin":549,"end":736},"obj":"Sentence"},{"id":"T766","span":{"begin":737,"end":758},"obj":"Sentence"},{"id":"T767","span":{"begin":759,"end":850},"obj":"Sentence"},{"id":"T768","span":{"begin":851,"end":887},"obj":"Sentence"},{"id":"T769","span":{"begin":888,"end":996},"obj":"Sentence"},{"id":"T770","span":{"begin":997,"end":1074},"obj":"Sentence"},{"id":"T771","span":{"begin":1075,"end":1111},"obj":"Sentence"},{"id":"T772","span":{"begin":1112,"end":1175},"obj":"Sentence"},{"id":"T773","span":{"begin":1176,"end":1363},"obj":"Sentence"},{"id":"T774","span":{"begin":1364,"end":1514},"obj":"Sentence"},{"id":"T775","span":{"begin":1515,"end":1533},"obj":"Sentence"},{"id":"T776","span":{"begin":1534,"end":1576},"obj":"Sentence"},{"id":"T777","span":{"begin":1577,"end":1946},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T256","span":{"begin":553,"end":558},"obj":"Phenotype"},{"id":"T257","span":{"begin":648,"end":653},"obj":"Phenotype"},{"id":"T258","span":{"begin":1180,"end":1185},"obj":"Phenotype"},{"id":"T259","span":{"begin":1275,"end":1280},"obj":"Phenotype"},{"id":"T260","span":{"begin":1674,"end":1679},"obj":"Phenotype"},{"id":"T261","span":{"begin":1836,"end":1855},"obj":"Phenotype"}],"attributes":[{"id":"A256","pred":"hp_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A257","pred":"hp_id","subj":"T257","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A258","pred":"hp_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A259","pred":"hp_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A260","pred":"hp_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A261","pred":"hp_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/HP_0002878"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"1962","span":{"begin":58,"end":70},"obj":"Species"},{"id":"1963","span":{"begin":559,"end":567},"obj":"Species"},{"id":"1964","span":{"begin":1186,"end":1194},"obj":"Species"},{"id":"1965","span":{"begin":1738,"end":1750},"obj":"Species"},{"id":"2077","span":{"begin":472,"end":483},"obj":"Chemical"},{"id":"2078","span":{"begin":870,"end":881},"obj":"Chemical"},{"id":"2079","span":{"begin":1094,"end":1105},"obj":"Chemical"}],"attributes":[{"id":"A1962","pred":"tao:has_database_id","subj":"1962","obj":"Tax:11118"},{"id":"A1963","pred":"tao:has_database_id","subj":"1963","obj":"Tax:9606"},{"id":"A1964","pred":"tao:has_database_id","subj":"1964","obj":"Tax:9606"},{"id":"A1965","pred":"tao:has_database_id","subj":"1965","obj":"Tax:11118"},{"id":"A2077","pred":"tao:has_database_id","subj":"2077","obj":"MESH:C502936"},{"id":"A2078","pred":"tao:has_database_id","subj":"2078","obj":"MESH:C462182"},{"id":"A2079","pred":"tao:has_database_id","subj":"2079","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group\nFavipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg\nActive comparator: favipiravir group\nOn the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days\nActive comparator: tocilizumab group\nThe first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):\nClinical cure rate\nSecondary (14 days after taking medicine):\nViral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020"}

PMC:7283670 / 88400-90346 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7283670 / 88400-90346 JSON TXT